原发性肝癌分期方法的比较研究
摘要
原发性肝癌分期方法的比较研究
目的
评估原发性肝癌五种分期方法的预后价值，包括三种临床分期方法：Okuda分期、CLIP(Cancer of The Liver Italian Program，CLIP)评分、LCSGJ(Liver Cancer Study Group of Japan，LCSGJ)第四版TNM(tumor-node-metastasis，TNM)分期及两种病理分期方法：UICC(International Union Against Cancer)／AJCC(American Joint Committee on Caner)第五版及第六版TNM分期，探讨其临床应用价值。
材料和方法
回顾性分析自1995年1月至1999年12月196例根治切除原发性肝癌的临床病理及随访资料。用log-rank检验进行生存率的单因素比较，用Cox回归进行多因素分析。用线性趋势卡方检验、似然比卡方检验、Harrell's c-指数(concordant index，c-指数)评估各分期系统的同质性、判别力，用AIC(Akaike Information Criterion，AIC)寻找最佳的预后模型。统计分析用SPSS和S-PLUS完成。
结果
本组患者1、3、5年生存率分别为84.7％、64.1％、34.9％，中位生存时间41个月。单因素分析显示就诊时症状、白蛋白水平、肝硬化、门静脉高压、Child分级、肿瘤大体类型(单结节／多结节)、AFP(Alpha-fetoprotein，AFP)水平、门静脉瘤栓、肿瘤直径、微血管受侵、侵犯临近脏器、淋巴结转移对预后的影响有统计学显著意义；多因素分析显示，淋巴结转移、Child-Pugh分级、门静脉瘤栓、肿瘤大体类型、门静脉高压、微血管侵犯是预后的独立负相关因素。临床分期方法中，CLIP评分的同质性、单调性、判别力最佳。病理分期方法中，UICC／AJCC第六版TNM分期的同质性、单调性、判别力优于第五版UICC／AJCC TNM分期。CLIP评分和UICC／AJCC第六版TNM分期的统计学
Objective
To evaluate the prognostic value of five staging systems for HCC (hepatocellular
carcinoma), including three clinical staging systems and two pathologic staging systems. The clinical staging systems evaluated were Okuda stage、CLIP (Cancer of The Liver Italian Program, CLIP) scoring system and the 4~(th) edition of LCSGJ (Liver Cancer Study Group of Japan, LCSGJ) TNM (tumor-node-metastasis, TNM) staging system. The pathologic staging systems compared were the 5th and 6th edition of UICC (International Union Against Cancer) /AJCC (American Joint Committee on Caner) TNM staging system.
Materials and methods
Clinicopathologic and follow-up data of 196 patients with curative resection of HCC from January 1995 to December 1999 were retrospectively studied. Univariate analysis of the prognostic significance of various clinicopathologic characteristics was performed using log rank test. Multivariate analysis was performed using Cox regression model. Linear trend chi-square test, likelihood ratio test and Harrel's concordant index were used to compare the homogeneity, discriminatory capacity, and monotonicity of gradients. AIC (Akaike information criterion, AIC) was also calculated to find the most efficient model.
Results
1, 3, and 5-year survival rates were 84.7%、64.1% and 34.9%, respectively, and median survival time was 41 months. Survival was significantly worse in those with symptoms at presentation, lower level of albumin, cirrhosis, portal hypertension, higher Child score, multiple tumors, higher AFP (Alpha-fetoprotein AFP) level, tumor
目的
评估原发性肝癌五种分期方法的预后价值，包括三种临床分期方法：Okuda分期、CLIP(Cancer of The Liver Italian Program，CLIP)评分、LCSGJ(Liver Cancer Study Group of Japan，LCSGJ)第四版TNM(tumor-node-metastasis，TNM)分期及两种病理分期方法：UICC(International Union Against Cancer)／AJCC(American Joint Committee on Caner)第五版及第六版TNM分期，探讨其临床应用价值。
材料和方法
回顾性分析自1995年1月至1999年12月196例根治切除原发性肝癌的临床病理及随访资料。用log-rank检验进行生存率的单因素比较，用Cox回归进行多因素分析。用线性趋势卡方检验、似然比卡方检验、Harrell's c-指数(concordant index，c-指数)评估各分期系统的同质性、判别力，用AIC(Akaike Information Criterion，AIC)寻找最佳的预后模型。统计分析用SPSS和S-PLUS完成。
结果
本组患者1、3、5年生存率分别为84.7％、64.1％、34.9％，中位生存时间41个月。单因素分析显示就诊时症状、白蛋白水平、肝硬化、门静脉高压、Child分级、肿瘤大体类型(单结节／多结节)、AFP(Alpha-fetoprotein，AFP)水平、门静脉瘤栓、肿瘤直径、微血管受侵、侵犯临近脏器、淋巴结转移对预后的影响有统计学显著意义；多因素分析显示，淋巴结转移、Child-Pugh分级、门静脉瘤栓、肿瘤大体类型、门静脉高压、微血管侵犯是预后的独立负相关因素。临床分期方法中，CLIP评分的同质性、单调性、判别力最佳。病理分期方法中，UICC／AJCC第六版TNM分期的同质性、单调性、判别力优于第五版UICC／AJCC TNM分期。CLIP评分和UICC／AJCC第六版TNM分期的统计学
Objective
To evaluate the prognostic value of five staging systems for HCC (hepatocellular
carcinoma), including three clinical staging systems and two pathologic staging systems. The clinical staging systems evaluated were Okuda stage、CLIP (Cancer of The Liver Italian Program, CLIP) scoring system and the 4~(th) edition of LCSGJ (Liver Cancer Study Group of Japan, LCSGJ) TNM (tumor-node-metastasis, TNM) staging system. The pathologic staging systems compared were the 5th and 6th edition of UICC (International Union Against Cancer) /AJCC (American Joint Committee on Caner) TNM staging system.
Materials and methods
Clinicopathologic and follow-up data of 196 patients with curative resection of HCC from January 1995 to December 1999 were retrospectively studied. Univariate analysis of the prognostic significance of various clinicopathologic characteristics was performed using log rank test. Multivariate analysis was performed using Cox regression model. Linear trend chi-square test, likelihood ratio test and Harrel's concordant index were used to compare the homogeneity, discriminatory capacity, and monotonicity of gradients. AIC (Akaike information criterion, AIC) was also calculated to find the most efficient model.
Results
1, 3, and 5-year survival rates were 84.7%、64.1% and 34.9%, respectively, and median survival time was 41 months. Survival was significantly worse in those with symptoms at presentation, lower level of albumin, cirrhosis, portal hypertension, higher Child score, multiple tumors, higher AFP (Alpha-fetoprotein AFP) level, tumor
引文
1. Carr BI, Flickinger JC, Lotze MT. Hepatobiliary cancers. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer; Principles and Practice of Oncology, 5th ed. Philadelphia, Lippincott-Raven, 1997, pp. 1087-1114.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-85.
3. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma-epidemiologic considerations. Hepatology 1982; 2(suppl):21S.
4. Kew MC, Rossouw E, Hodkinsson J, et al. Hepatitis B virus status of Southern African blacks with hepatocellular carcinoma: comparison between rural and urban populations. Hepatology 1983; 3:65-68.
5. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
6. EL-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340:745-750.
7. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 462:381-393.
8. Parkin DM. The global burden of cancer. Semin Cancer Biol 1998; 8:219-235.
9．李连第，张思维，鲁凤珠，等．中国恶性肿瘤死亡谱及分类构成特征研究．中华肿瘤杂志，1997，19：323
10. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, (Eds). Liver Cancer. New York: Churchill Livingstone 1997: 13-28.
11. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
12. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31:133-141.13. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32:233-238.
14. CLIP. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-845.
15. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survivals. Hepatology 1992; 16:132-137.
16. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
17. Wang TL, Yap IL, Tan YO. Hepatocellular carcinoma—a case series of 104 patients. Ann Acad Med Singapore 1991; 20:215-218.
18. ScheeleJ.Hepatectomyforlivermetastases.Br J Surgl993; 80:274-6.
19. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-1021.
20. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790-799.
21. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 39:1434-1440.
22. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32:1224-1229.
23. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34:707-713.
24. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP Score) for hepatocellular carcinoma in 662 Japanese??Patients. Hepatology 2002, 34: 529-534.
25. Chen MF, Hwang TL, Jeng LB, et al. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989;124:1025-1028.
26. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104-1110.
27. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106:1618-1624.
28. Sangro B, Herraiz M, Martinez-Gonzalez MA, et al. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery I998;124:5750583.
29. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775.
30. Dulla PL, Pozzi NR, Sonza M, et al. Diagnosis imaging and interventional therapy in hepatocarcinoma. Muticenter study of 290 cases. Radiol Med 1997;94:30-36.
31. Yamamoto K, Masuzawa M, Kato M, et al. Evaluation of combined therapy with chemoembolizaiton and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol 1997;24:50-55.
32. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alphafetoprotein levels. J Clin Gastroenterol 2000;31:302-308.
33. Lerose R, Molinari R, Rocchi E, et al. Prognosis features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 2001;37:239-245.
34. Child CG, Turcotte JG. The Liver and Portal Hypertension. Philadelphia, W.B. Saunders. 1964, pp 50-51.
35. Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928.
36. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic??system for hepatocellular carcinoma: a retrospective study of 435 patients.Hepatology. 1998;28:751-755.
37. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd edition. Tokyo: Kanehara: 1992.
38. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th edition. Tokyo: Kanehara: 2000.
39. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer.2002;94:1760-1769.
40. Vauthey JN, Lauwers GY, Esnaola NF, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.
41. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual 5th edition. Philadelphis, PA: Lippincott-Raven. 1997.
42. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. 6th edition. New York: Springer-Verleg. Inc. 2002.
43. Alex S, Befeler M, Adrian M, et al. Hepatocellular Carcinoma: Diagnosis and Treatment. Gastroenterology 2002; 122:1609-1619.
44. Primack A, Vogel Ch, Kyalwazi S, Ziegler J, Simon R, Anthony P. A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients. Cancer 1975;35:1357-1364.
45. Chlebowski R, Tong M, Weissman J, et al. Hepatocellular carcinoma. Dianostic and prognostic features in north American patients. Cancer 1984;53:2701-2706.
46. Attali P, Prod' Homme, Pelletier G, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for selection of patients with prolonged survival. Cancer 1987;45:2108-2111.
47. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988;15;l-31.
48. Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC. Prognostic factors for??survival in hepatocellular carcinoma. Cancer Res 1988;48:7314-7318.
49. Calvet X, Bruix J, Bru C, et al. Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. J Hepatol 1990; 10:311-317.
50. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-2222.
51. Ueno S, Tannabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. J Hepatol Res 2002; 24:395-403.
52. Pugh RNH, Myrray-Lyon IM, Dawson JL, et al. Transsection of the esophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
53. Foster JH, Ellison LH, Donovan TJ, et al. Quantity and quality of survival after portosystemic shunts. Am J Surg 1971; 121:490-501.
54. Campbell DP, Parker DE, Anagnostopoulos CE. Survival prediction in portacaval shunts: a computerized statistical analysis. Am J Surg 1973; 126:748-751.
55. Cameron JL, Zuideman GD, Smith GW, et al. Mesocaval shunts for the control of bleeding esophageal varices. Surgery 1979; 85:257-262.
56. Langer B, Taylor B, Mackenzie D, et al. Further report of a prospective randomized trial comparing distal splenorenal shunt with end-to-side portacaval shunt. Gastroenterology 1985; 88:424-9.
57. Teres J, Baroni R, Bordas J, et al. Randomized trial of portacaval shunt, stapling transaction and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987; 4:159-67.
58. Henderson JM, Kutner MH, Bain RP. Fist-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982; 163:515-8.
59. Beuers U, Jager F, Wahllander A, et al. Prognositic value of the intravenous 14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 1991; 50:212-8.
60. Levy L, Sherman M, the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;??50:881-885.
61. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP Score) for hepatocellular carcinoma in 662 Japanese Patients. Hepatology 2002, 34: 529-534.
62. Fanco D, Capussotti L, Smadja C, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology. 1990; 98:733-8.
63. Nonami T, Hrada A, Kurokawa T, et al. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997; 44:798-802.
64. Fan ST, Lai EC, Lo CM, et al. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995; 198-203.
65. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Bri J Surg. 1997 84:1255-1259.
66. Lau W, Legung K, Legung TW, et al. A logical approach to hepatocellular carcinoma presenting with jaundice. Ann Surg 1997; 225:281-5.
67. Adler M, VanLaethem J, Gilbert A, et al. Factors influencing survival at one year in patients with nonbiliary hepatic parenchymal cirrhosis. Digest Dis Sci 1990;35:1-5.
68. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33:836-842.
69. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systemic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
70. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266-2273.
71. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018-1022.
72. Llovet JM, Bruix J, Fuster J, et al. Long-term outcome after radical treatment??for hepatocellular carcinoma: a single center experience. Hepatology 1998;28:340A.
73. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power.Hepatology 1998; 27:1572-1577.
74. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259-262.
75. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma.Results of a randomizated controlled trial in a single institution. Hepatology 1998;27:1578-1583.
76. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.Gastroenterology 1995; 109:917-922.
77. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67:773-5.
78. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221-228.
79. Ringe B, Pichlmayr R, Wittekind C, Tusch G Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270-285.
80. Moreno P, Jaurrieta E, Figueras J, et al. Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma? Transplant Proc 1995; 27:2296-2298.
81. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
82. Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88:538-543.
83. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106:720-7.84.张智坚,吴孟超,沈锋,等.TNM分期对评价肝细胞癌切除术预后的价值.中华肿瘤杂志, 1999, 21:293-295.
85. Asahar T, Dohi K, Katayama K, et al. Factors affecting postoperative prognosis in the solitary-nodule type of hepatocellular carcinoma: experience of 132 cases in our institute. Hiroshima J Med Sci 1998; 47:99-104.
86. Olthoff KM. Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transplant Surg 1998; 4(5 Suppl 1):S98-104.
87. Lau H, Fan ST, Ng 10, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998;83:2302-11.
88. Paquet KJ, Gad HA, Lazar A, et al. Analysis of factors affection outcome after hepatcetomy of patients with liver cirrhosis and small hepatocellular carcinoma.Eur J Surg 1998; 164:513-519.
89. Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques,complications, and prognostic factors. J Hepato-Biliay-Pancreat Surg 1998;5:7-13.
90. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepato-Biliay-Pancreat Surg 1998; 5:29-34.
91. Mise K, Tashiro S, Yogita S, et al. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosi.Clin Cancer Res 1998; 4:1475-1482.
92. Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy.Cancer 1998; 83:58-63.
93. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21 WAF1,and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18:555-64.
94. Otto G, Heuschen U, Hofmann WJ, et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective??analysis. Ann Surg 1998; 227:424-432.
95. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumor ablation. Br J Cancer 1998; 77:776-82.
96. Lise M, Bacchetti S, Da Pian P, et al. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer 1998; 82:1028-1036.
97. Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after reat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998; 227:80-5.
98. Chen NIF, Jeng LB. Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S329-34.
99. Terri B, Laurent-Puig P, Belghitti J, et al. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in Fance. Int J Cancer 1997; 74:614-9.
100.Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528-535.
101.Kobayashi S, Hayashi H, Itoh Y, et al. Detection of minus-strand hepatitis C virus RNA in tumor tissues of hepatocellular carcinoma. Cancer 1994; 73:48-52.
102.Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
103.Adachi E, Maeda T, Matsuma T, et al. Risk factors for introhepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108:768-775.
104.Chiu JH, Wu LH, Kao HL, et al. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma. Hepatology 1993; 18:96-102.
105.Ueno S, Tanabe G, Yoshida A, et al. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999; 86:248-254.
106.Nigam A, Zhurak M, Boitnott JR, et al. Factors affecting survival in Westernpatients following curative resection for hepatocellular carcinoma. Gatroenterology 1996; 77:2022-2031.
107.Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrency of hepatocellular carcinoma after hepatectomy: result of multivariate analysis. Ann Surg 1996; 224:591-595.
108.Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996; 77:1050-5.
109.Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with respectable hepatocellular carcinoma. Surgery 2000; 127:603-608.
110.Sasaki Y, Imaoka S, Masutani S, et al. Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma.Surgery 1992; 112:515-521.
111.Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83:1219-1222.
112.Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study. Gastroenterology 1995; 108:812-817.
113.Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: A clinico-histopathologic study of 804 North American patients. Am J Clin Path 1996; 105:65-75.
114.Yamasaki S, Makuuchi M, Kosuga T, et al. Staging system of hepatocellular carcinoma in general rule for liver cancer, 4th version and TNM classification.Kan Tan Sui 2000; 41:473-480.
115.Ikai I, Yamaoka Y. Natiowide survey of hepatocellular carcinoma in Japan based on macroscopic stage in"Classification of Primary Liver Cancer (3rd Edition)". Kan Tan Sui 2000; 41:481-490.
116.Feinsten AR. Clinical Biostatistics XVI. The process of prognostic stratification. Clin Pharmocol Ther 1972; 13:609-624.117.Stone M: Akaike's criteria. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Chichester: Wiley, 1998:123-124.
118.Harrell FE Jr., Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med; 1984, 3: 143-152.
119.Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001;88:515-522.
120.Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96: 1243-1250.
121.Jwo Sc, Chiu JH, Chau GY, et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992;16:1367-1371.
122.Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Sug 1994; 129:738-742.
123.Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: Experience of 480 cases. Hepatogastroenterology 1993;40:328-332.
124.Bilimoria MM, Lauwers GY, Doherty DA, et at. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Sug 2001; 136:528-535.
125.Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28-35.
126.Hemming AW, Cattral MS, Reed Al, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233:652-659.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-85.
3. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma-epidemiologic considerations. Hepatology 1982; 2(suppl):21S.
4. Kew MC, Rossouw E, Hodkinsson J, et al. Hepatitis B virus status of Southern African blacks with hepatocellular carcinoma: comparison between rural and urban populations. Hepatology 1983; 3:65-68.
5. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
6. EL-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340:745-750.
7. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 462:381-393.
8. Parkin DM. The global burden of cancer. Semin Cancer Biol 1998; 8:219-235.
9．李连第，张思维，鲁凤珠，等．中国恶性肿瘤死亡谱及分类构成特征研究．中华肿瘤杂志，1997，19：323
10. Bosch F. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, (Eds). Liver Cancer. New York: Churchill Livingstone 1997: 13-28.
11. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-67.
12. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31:133-141.13. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32:233-238.
14. CLIP. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-845.
15. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survivals. Hepatology 1992; 16:132-137.
16. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
17. Wang TL, Yap IL, Tan YO. Hepatocellular carcinoma—a case series of 104 patients. Ann Acad Med Singapore 1991; 20:215-218.
18. ScheeleJ.Hepatectomyforlivermetastases.Br J Surgl993; 80:274-6.
19. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-1021.
20. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229:790-799.
21. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 39:1434-1440.
22. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000; 32:1224-1229.
23. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34:707-713.
24. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP Score) for hepatocellular carcinoma in 662 Japanese??Patients. Hepatology 2002, 34: 529-534.
25. Chen MF, Hwang TL, Jeng LB, et al. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989;124:1025-1028.
26. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104-1110.
27. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106:1618-1624.
28. Sangro B, Herraiz M, Martinez-Gonzalez MA, et al. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery I998;124:5750583.
29. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775.
30. Dulla PL, Pozzi NR, Sonza M, et al. Diagnosis imaging and interventional therapy in hepatocarcinoma. Muticenter study of 290 cases. Radiol Med 1997;94:30-36.
31. Yamamoto K, Masuzawa M, Kato M, et al. Evaluation of combined therapy with chemoembolizaiton and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol 1997;24:50-55.
32. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alphafetoprotein levels. J Clin Gastroenterol 2000;31:302-308.
33. Lerose R, Molinari R, Rocchi E, et al. Prognosis features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 2001;37:239-245.
34. Child CG, Turcotte JG. The Liver and Portal Hypertension. Philadelphia, W.B. Saunders. 1964, pp 50-51.
35. Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928.
36. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic??system for hepatocellular carcinoma: a retrospective study of 435 patients.Hepatology. 1998;28:751-755.
37. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd edition. Tokyo: Kanehara: 1992.
38. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th edition. Tokyo: Kanehara: 2000.
39. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer.2002;94:1760-1769.
40. Vauthey JN, Lauwers GY, Esnaola NF, et al: Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-1536.
41. Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual 5th edition. Philadelphis, PA: Lippincott-Raven. 1997.
42. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. 6th edition. New York: Springer-Verleg. Inc. 2002.
43. Alex S, Befeler M, Adrian M, et al. Hepatocellular Carcinoma: Diagnosis and Treatment. Gastroenterology 2002; 122:1609-1619.
44. Primack A, Vogel Ch, Kyalwazi S, Ziegler J, Simon R, Anthony P. A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients. Cancer 1975;35:1357-1364.
45. Chlebowski R, Tong M, Weissman J, et al. Hepatocellular carcinoma. Dianostic and prognostic features in north American patients. Cancer 1984;53:2701-2706.
46. Attali P, Prod' Homme, Pelletier G, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for selection of patients with prolonged survival. Cancer 1987;45:2108-2111.
47. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988;15;l-31.
48. Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC. Prognostic factors for??survival in hepatocellular carcinoma. Cancer Res 1988;48:7314-7318.
49. Calvet X, Bruix J, Bru C, et al. Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. J Hepatol 1990; 10:311-317.
50. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-2222.
51. Ueno S, Tannabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. J Hepatol Res 2002; 24:395-403.
52. Pugh RNH, Myrray-Lyon IM, Dawson JL, et al. Transsection of the esophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
53. Foster JH, Ellison LH, Donovan TJ, et al. Quantity and quality of survival after portosystemic shunts. Am J Surg 1971; 121:490-501.
54. Campbell DP, Parker DE, Anagnostopoulos CE. Survival prediction in portacaval shunts: a computerized statistical analysis. Am J Surg 1973; 126:748-751.
55. Cameron JL, Zuideman GD, Smith GW, et al. Mesocaval shunts for the control of bleeding esophageal varices. Surgery 1979; 85:257-262.
56. Langer B, Taylor B, Mackenzie D, et al. Further report of a prospective randomized trial comparing distal splenorenal shunt with end-to-side portacaval shunt. Gastroenterology 1985; 88:424-9.
57. Teres J, Baroni R, Bordas J, et al. Randomized trial of portacaval shunt, stapling transaction and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987; 4:159-67.
58. Henderson JM, Kutner MH, Bain RP. Fist-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982; 163:515-8.
59. Beuers U, Jager F, Wahllander A, et al. Prognositic value of the intravenous 14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 1991; 50:212-8.
60. Levy L, Sherman M, the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;??50:881-885.
61. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP Score) for hepatocellular carcinoma in 662 Japanese Patients. Hepatology 2002, 34: 529-534.
62. Fanco D, Capussotti L, Smadja C, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology. 1990; 98:733-8.
63. Nonami T, Hrada A, Kurokawa T, et al. Hepatic resection for hepatocellular carcinoma. Am J Surg 1997; 44:798-802.
64. Fan ST, Lai EC, Lo CM, et al. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995; 198-203.
65. Lau H, Man K, Fan ST, et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Bri J Surg. 1997 84:1255-1259.
66. Lau W, Legung K, Legung TW, et al. A logical approach to hepatocellular carcinoma presenting with jaundice. Ann Surg 1997; 225:281-5.
67. Adler M, VanLaethem J, Gilbert A, et al. Factors influencing survival at one year in patients with nonbiliary hepatic parenchymal cirrhosis. Digest Dis Sci 1990;35:1-5.
68. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33:836-842.
69. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systemic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
70. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89:2266-2273.
71. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients. Prognostic value of preoperative portal pressure. Gastroenterology 1996; 111:1018-1022.
72. Llovet JM, Bruix J, Fuster J, et al. Long-term outcome after radical treatment??for hepatocellular carcinoma: a single center experience. Hepatology 1998;28:340A.
73. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power.Hepatology 1998; 27:1572-1577.
74. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259-262.
75. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma.Results of a randomizated controlled trial in a single institution. Hepatology 1998;27:1578-1583.
76. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.Gastroenterology 1995; 109:917-922.
77. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993; 67:773-5.
78. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214:221-228.
79. Ringe B, Pichlmayr R, Wittekind C, Tusch G Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15:270-285.
80. Moreno P, Jaurrieta E, Figueras J, et al. Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma? Transplant Proc 1995; 27:2296-2298.
81. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
82. Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000; 88:538-543.
83. Izumi R, Shimizu K, Li T, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106:720-7.84.张智坚,吴孟超,沈锋,等.TNM分期对评价肝细胞癌切除术预后的价值.中华肿瘤杂志, 1999, 21:293-295.
85. Asahar T, Dohi K, Katayama K, et al. Factors affecting postoperative prognosis in the solitary-nodule type of hepatocellular carcinoma: experience of 132 cases in our institute. Hiroshima J Med Sci 1998; 47:99-104.
86. Olthoff KM. Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transplant Surg 1998; 4(5 Suppl 1):S98-104.
87. Lau H, Fan ST, Ng 10, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998;83:2302-11.
88. Paquet KJ, Gad HA, Lazar A, et al. Analysis of factors affection outcome after hepatcetomy of patients with liver cirrhosis and small hepatocellular carcinoma.Eur J Surg 1998; 164:513-519.
89. Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques,complications, and prognostic factors. J Hepato-Biliay-Pancreat Surg 1998;5:7-13.
90. Regalia E, Fassati LR, Valente U, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepato-Biliay-Pancreat Surg 1998; 5:29-34.
91. Mise K, Tashiro S, Yogita S, et al. Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosi.Clin Cancer Res 1998; 4:1475-1482.
92. Taketomi A, Shimada M, Shirabe K, et al. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy.Cancer 1998; 83:58-63.
93. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21 WAF1,and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18:555-64.
94. Otto G, Heuschen U, Hofmann WJ, et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective??analysis. Ann Surg 1998; 227:424-432.
95. Honda K, Sbisa E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumor ablation. Br J Cancer 1998; 77:776-82.
96. Lise M, Bacchetti S, Da Pian P, et al. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer 1998; 82:1028-1036.
97. Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after reat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998; 227:80-5.
98. Chen NIF, Jeng LB. Partial hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S329-34.
99. Terri B, Laurent-Puig P, Belghitti J, et al. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in Fance. Int J Cancer 1997; 74:614-9.
100.Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001; 136:528-535.
101.Kobayashi S, Hayashi H, Itoh Y, et al. Detection of minus-strand hepatitis C virus RNA in tumor tissues of hepatocellular carcinoma. Cancer 1994; 73:48-52.
102.Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
103.Adachi E, Maeda T, Matsuma T, et al. Risk factors for introhepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108:768-775.
104.Chiu JH, Wu LH, Kao HL, et al. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma. Hepatology 1993; 18:96-102.
105.Ueno S, Tanabe G, Yoshida A, et al. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999; 86:248-254.
106.Nigam A, Zhurak M, Boitnott JR, et al. Factors affecting survival in Westernpatients following curative resection for hepatocellular carcinoma. Gatroenterology 1996; 77:2022-2031.
107.Ko S, Nakajima Y, Kanehiro H, et al. Significant influence of accompanying chronic hepatitis status on recurrency of hepatocellular carcinoma after hepatectomy: result of multivariate analysis. Ann Surg 1996; 224:591-595.
108.Shirabe K, Takenaka K, Taketomi A, et al. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996; 77:1050-5.
109.Tsai TJ, Chau GY, Lui WY, et al. Clinical significance of microscopic tumor venous invasion in patients with respectable hepatocellular carcinoma. Surgery 2000; 127:603-608.
110.Sasaki Y, Imaoka S, Masutani S, et al. Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma.Surgery 1992; 112:515-521.
111.Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83:1219-1222.
112.Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study. Gastroenterology 1995; 108:812-817.
113.Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: A clinico-histopathologic study of 804 North American patients. Am J Clin Path 1996; 105:65-75.
114.Yamasaki S, Makuuchi M, Kosuga T, et al. Staging system of hepatocellular carcinoma in general rule for liver cancer, 4th version and TNM classification.Kan Tan Sui 2000; 41:473-480.
115.Ikai I, Yamaoka Y. Natiowide survey of hepatocellular carcinoma in Japan based on macroscopic stage in"Classification of Primary Liver Cancer (3rd Edition)". Kan Tan Sui 2000; 41:481-490.
116.Feinsten AR. Clinical Biostatistics XVI. The process of prognostic stratification. Clin Pharmocol Ther 1972; 13:609-624.117.Stone M: Akaike's criteria. In: Armitage P, Colton T, eds. Encyclopedia of Biostatistics. Chichester: Wiley, 1998:123-124.
118.Harrell FE Jr., Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med; 1984, 3: 143-152.
119.Nagasue N, Ono T, Yamanoi A, et al. Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001;88:515-522.
120.Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96: 1243-1250.
121.Jwo Sc, Chiu JH, Chau GY, et al. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992;16:1367-1371.
122.Chen MF, Hwang TL, Jeng LB, et al. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Sug 1994; 129:738-742.
123.Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: Experience of 480 cases. Hepatogastroenterology 1993;40:328-332.
124.Bilimoria MM, Lauwers GY, Doherty DA, et at. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Sug 2001; 136:528-535.
125.Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg 1995; 169:28-35.
126.Hemming AW, Cattral MS, Reed Al, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233:652-659.